Phase I trial evaluating the immunogenicity of H4IC in patients with latent tuberculosis who have received the BCG vaccine
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2012
At a glance
- Drugs H4IC (Primary)
- Indications Tuberculosis
- Focus Pharmacodynamics
- 17 Jan 2012 Enrolment was completed in 2008, and analysis of the clinical samples is ongoing, according to sanofi pasteur.
- 04 Dec 2007 Status change from planning to recruiting.
- 26 Mar 2007 New trial record.